EMPE Diagnostics is redefining infectious disease diagnostics with rapid, affordable, and scalable solutions designed for global impact. As we approach market entry with breakthrough products, EMPE offers investors a rare opportunity to participate in both strong commercial growth and meaningful global health impact.

By investing in EMPE, you are backing a company poised to improve healthcare outcomes for millions—through faster, more accurate diagnosis that enables better treatment decisions, reduces system-wide healthcare costs, and improves quality of life worldwide.

1. Breakthrough Technology, Built for Scale
EMPE Diagnostics develops next-generation molecular diagnostics focused on TB and drug-resistant infections. Our proprietary, open-platform technologies integrate seamlessly into existing laboratory infrastructure, keeping adoption costs low and enabling rapid deployment. This makes our solutions uniquely suited for large-scale implementation, particularly in high-burden and resource-limited markets.

2. World-Class Scientific and Commercial Leadership
Founded on innovations from the Karolinska Institute, EMPE Diagnostics is led by a seasoned team of scientific and industry experts spanning molecular biology, biochemistry, and business development. This blend of deep science and commercial execution positions the company to successfully translate innovation into global market leadership.

3. Large, Underserved Market Opportunity
The molecular diagnostics market is growing rapidly, yet diseases prevalent in low and middle-income countries remain significantly underserved. Large multinational players often overlook these markets due to pricing and cost constraints. EMPE Diagnostics fills this gap with a cost-efficient operating model anchored in India. With ISO 13485:2016-certified manufacturing facility/plant in Hyderabad, India and local sales and marketing, EMPE benefits from strong margins and scalable economics.

4. Strong Impact with Commercial Returns
EMPE Diagnostics delivers measurable social impact while pursuing attractive investor returns. Our diagnostics address critical unmet medical needs, enabling earlier detection and more effective treatment in regions where timely diagnosis can save lives. This alignment of impact and profitability strengthens long-term value creation.

5. Flexible Business Model with Expansion Potential
Our platforms are designed for affordability, ease of use, and compatibility with standard molecular lab equipment, allowing deployment across hospitals, clinics, and decentralized settings. This flexibility supports rapid expansion across India and into global markets, unlocking multiple revenue streams and long-term growth potential.

EMPE Diagnostics represents a compelling investment at the intersection of cutting-edge science, scalable economics, and global health impact.

Our Growth Strategy

1. Product Development and Expansion:
Our CDSCO approved MDR-TB test has now been complemented with a range of new products spanning from TBDx – a fast and reliable TB +/- screening test to MDR and pre-XDR in qPCR format adding significant improvements to the original MDR-TB test. Most interestingly the new tests will be sold as freeze-dried products which will simplify logistics significantly. With these tests we seed the basis for a strong market expansion in response to the requirements from clinicians, regulatory bodies and governments. Beyond TB we are in contact with international organisations issuing requirements for tests in high demand for low and middle-income countries.

2. Strategic Partnerships:
EMPE Diagnostics has over time received development grants from international organisations such as Gates Foundation and the EIC and is actively working with international organisations to expand our global reach as well as for funding of new product initiatives.
We are over time building an international presence with support from these organisations and are seeking non-dilutive grants to expand our capacity.

3. Global Market Penetration:
While we from our commercial base in India also enjoy a strong presence in Asia, we are actively looking to expand our market reach to Africa, where the need for cost-effective diagnostics is huge. Expansion is to some extent governed by which countries will allow for a smooth approval process. In that context, we are also working with WHO to obtain endorsement and eventually WHO Prequalification (PQ) which in turn will pave the way for a smoother expansion in many of the export territories.

EMPE Diagnostics has built strong, defensible value through a combination of differentiated technology, regulatory maturity, and capital-efficient operations. Our padlock probe–based platform enables highly complex AMR genotyping, while our ISO 13485:2016–certified manufacturing facility in Hyderabad—re-certified with outstanding results in July 2025—demonstrates a robust and consistently high-performing quality system.

Recent product launches confirm our ability to develop and commercialize new diagnostics rapidly and cost-effectively, guided by close collaboration with clinicians to ensure clear clinical relevance and fast market adoption.

With most of our cost base in India, EMPE benefits from exceptional unit economics across manufacturing and commercialization. This allows investor capital to directly fuel large-scale growth. Under conservative assumptions, the company is positioned to reach cash-flow positivity within two years of investment by capturing just 3% of the Indian market.



Built on realistic, disciplined financial planning and supported by strong international interest—particularly from Africa and Southeast Asia—EMPE Diagnostics offers investors a clear path to scalable growth, early profitability, and meaningful global health impact.